Ivermectin effectively inhibits hepatitis E virus replication, requiring the host nuclear transport protein importin α1

We show that ivermectin, an FDA-approved anti-parasitic drug, effectively inhibits infection with hepatitis E virus (HEV) genotypes 1 and 3 in a range of cell culture models, including hepatic and extrahepatic cells. Long-term treatment showed no clear evidence of the development of drug resistance....

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yunlong, Miao, Zhijiang, Li, Pengfei, Zhang, Ruyi, Kainov, Denis E., Ma, Zhongren, de Man, Robert A., Peppelenbosch, Maikel P., Pan, Qiuwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119233/
https://www.ncbi.nlm.nih.gov/pubmed/33987753
http://dx.doi.org/10.1007/s00705-021-05096-w
Descripción
Sumario:We show that ivermectin, an FDA-approved anti-parasitic drug, effectively inhibits infection with hepatitis E virus (HEV) genotypes 1 and 3 in a range of cell culture models, including hepatic and extrahepatic cells. Long-term treatment showed no clear evidence of the development of drug resistance. Gene silencing of importin-α1, a cellular target of ivermectin and a key member of the host nuclear transport complex, inhibited viral replication and largely abolished the anti-HEV effect of ivermectin. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00705-021-05096-w.

Ejemplares similares